ANIX earnings: next report 2026-09-10, real EPS beat/miss history, analyst consensus Buy, P/E -11.80. Updated 2026-07-23.
Anixa Biosciences (ANIX) Research Hub
Anixa Biosciences (ANIX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.76 USD (-2.47%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -11.80, market cap 0.12B. This hub links to the full technical, earnings and options research available for ANIX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.76 USD (-2.47%) |
| 52-week range | 2.36 USD – 3.89 USD |
| Trend regime | Range |
| 14-day RSI | 30.8 (Bearish) |
| Trailing P/E | -11.80 |
| Market cap | 0.12B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-10 |
Available research for ANIX
Covered Call on ANIX: how it works, illustrative setup around the real 2.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ANIX: how it works, illustrative setup around the real 2.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ANIX: how it works, illustrative setup around the real 2.76 USD price, max profit/loss, breakeven and when to use it. Educational.
ANIX technical analysis: range, last 2.76 USD, RSI 30.8, 52w range 2.36 USD–3.89 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ANIX in?
Anixa Biosciences (ANIX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ANIX in an uptrend or downtrend?
As of 2026-09-11, ANIX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ANIX's trailing P/E ratio?
ANIX's trailing P/E is -11.80, with a market cap of 0.12B. See the earnings research page for full valuation detail.
When does ANIX next report earnings?
ANIX is next scheduled to report earnings on 2026-09-10, with a consensus EPS estimate of -0.08 USD.